{
    "clinical_study": {
        "@rank": "11595", 
        "arm_group": {
            "arm_group_label": "RDEA3170", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This study will determine the characteristics of absorption, metabolism, and excretion (AME)\n      of RDEA3170 following a single 10 mg dose of RDEA3170 oral solution with 500 microcuries\n      (\u00b5Ci) of [14 C]RDEA3170 in healthy adult male subjects."
        }, 
        "brief_title": "RDEA3170 AME Study", 
        "completion_date": {
            "#text": "November 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Body weight \u2265 50 kg (110 lbs.) and body mass index \u2265 18 and \u2264 30 kg/m2.\n\n          -  No clinically relevant abnormalities in vital signs, ECG, physical examination or\n             safety laboratory values.\n\n          -  Screening serum urate level \u2264 7.0 mg/dL.\n\n          -  Subject has a minimum of 1 bowel movement a day.\n\n        Exclusion Criteria:\n\n          -  History or suspicion of kidney stones.\n\n          -  History of gastrointestinal ulcers, Helicobacter pylori infection, or other disorders\n             of gastric pH.\n\n          -  History of previous surgery on the stomach or small intestine (appendectomy is\n             acceptable). Subject has donated blood or experienced significant blood loss (> 450\n             mL) within 12 weeks prior to Day 1 or has given a plasma donation within 6 weeks\n             prior to Day 1.\n\n          -  Inadequate venous access or unsuitable veins for repeated venipuncture."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01910506", 
            "org_study_id": "RDEA3170-106"
        }, 
        "intervention": {
            "arm_group_label": "RDEA3170", 
            "intervention_name": "RDEA3170 10 mg", 
            "intervention_type": "Drug", 
            "other_name": "RDEA3170 10 mg dose oral solution with 500 \u03bcCi of [14C]RDEA3170"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 8, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Madison", 
                    "country": "United States", 
                    "state": "Wisconsin", 
                    "zip": "53704"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 1 Absorption, Metabolism and Excretion Study of [14C]RDEA3170 Orally Administered to Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Ardea Biosciences, Inc.", 
            "last_name": "S. Baumgartner", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "PK profile in terms of AUC, Tmax, Cmax, t1/2, Ae, CLr, and  CL/F.\nAUC: area under the concentration-time curve; Tmax: time to reach maximum concentration; Cmax: maximum concentration; t1/2: apparent terminal half-life; Ae: amount of compound excreted in urine unchanged; CLr: renal clearance; CL/F: total body clearance corrected for bioavailability\nMetabolic profile of RDEA3170 in plasma, urine, and feces.\nExcretion in terms of recovery of radioactivity in urine and feces.", 
            "measure": "Characteristics of AME in terms of pharmacokinetics (PK), metabolism, and excretion", 
            "safety_issue": "No", 
            "time_frame": "Day 1 predose, 15, 30, 45 mins, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 24, 30, 36, 48, 54, 60, 72 hrs postdose (blood and plasma only); Day 1, -12 to 0, 0-6, 6-12, 12-24 hrs postdose (urine and feces only)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01910506"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Incidence of Adverse Events and Changes in Laboratory,  Electrocardiogram, and Vital Signs Parameters", 
            "safety_issue": "Yes", 
            "time_frame": "5 weeks"
        }, 
        "source": "Ardea Biosciences, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ardea Biosciences, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}